Clinical Trials

Schizophrenia

Luvadaxistat (NBI-1065844/TAK-831) was developed by Takeda Pharmaceutical Company Limited for the treatment of schizophrenia, and has completed several Phase I trials in healthy participants. In January 2018 the Phase II INTERACT multi-center, randomized, double-blind, placebo-controlled, parallel study was initiated to evaluate efficacy, safety, tolerability, and pharmacokinetics of three dose levels luvadaxistat as an adjunctive treatment of adult patients with negative symptoms of schizophrenia. For more information on the Phase II study of luvadaxistat, please visit clinicaltrials.gov.